Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
REPRONEX vs BRAVELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
REPRONEX (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth in women who do not have primary ovarian failure. It acts by binding to FSH receptors on granulosa cells, increasing c AMP and promoting follicular development and estrogen synthesis.
Bravelle (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth and maturation by binding to FSH receptors on granulosa cells, increasing c AMP production and promoting follicular development.
Induction of ovulation in oligo-ovulatory or anovulatory women with functional hypothalamic-pituitary dysfunction (WHO Group II),Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF)
Ovulation induction in anovulatory women with polycystic ovary syndrome (PCOS),Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF)
Men: 1000-2500 IU subcutaneously 3 times weekly for 6-12 months. Women: 75-300 IU subcutaneously or intramuscularly daily for 7-12 days.
For ovulation induction: 150 IU subcutaneously or intramuscularly once daily for 5 days, starting on day 3 or 5 of menstrual cycle. For controlled ovarian hyperstimulation: 150-225 IU subcutaneously or intramuscularly once daily for 5-7 days, then adjust based on response.
Terminal elimination half-life: 24-30 hours (menotropins); clinically, it supports daily dosing during ovarian stimulation
Terminal elimination half-life approximately 5-6 hours in healthy adults. Extended in renal impairment (up to 24 hours with Cr Cl <30 m L/min).
REPRONEX is a glycoprotein hormone that is cleared primarily by the liver and kidneys. The metabolic pathways involve proteolytic degradation. The terminal half-life is approximately 4-12 hours after subcutaneous administration.
Primarily metabolized in the liver via renal excretion; metabolic pathways not fully characterized.
Renal (approximately 80% as parent drug and metabolites); biliary/fecal (<5%)
Primarily renal: 95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal: 5% eliminated via feces.
Approximately 10%; mainly albumin
Approximately 10-20% bound to plasma proteins (albumin and α-1 acid glycoprotein).
0.2-0.5 L/kg; reflects distribution primarily in extracellular fluid
Approximately 0.3-0.5 L/kg. Distributing primarily in extracellular fluid; does not extensively penetrate tissues.
SC/IM: nearly 100%
Subcutaneous: 90-95% bioavailable relative to intramuscular route. Oral: not clinically used due to enzymatic degradation.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m²).
No specific guidelines exist for GFR-based dose modifications; use with caution in severe renal impairment (Cr Cl <30 m L/min) and monitor for adverse effects.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
No specific guidelines exist for Child-Pugh based modifications; use with caution in severe hepatic impairment and monitor for adverse effects.
Not recommended for use in pediatric patients (safety and efficacy not established).
Not indicated for use in pediatric patients; safety and efficacy not established.
No specific dose adjustment; use with caution due to potential for decreased renal function and increased risk of thromboembolic events.
Not indicated for use in geriatric patients; safety and efficacy not established.
REPRONEX should only be used by physicians who are experienced in infertility treatment and capable of monitoring ovarian response. Ovarian hyperstimulation syndrome (OHSS) may occur, which can be severe and potentially fatal. Multiple births have been reported.
Bravelle should only be used by physicians who are experienced in infertility treatment and can manage potential serious adverse events, including ovarian hyperstimulation syndrome (OHSS) and multiple gestations.
Risk of ovarian hyperstimulation syndrome (OHSS), which can be severe,Risk of multiple gestation,Thromboembolic events,Ovarian torsion,Pulmonary complications (e.g., atelectasis, adult respiratory distress syndrome)
Ovarian enlargement and ovarian hyperstimulation syndrome (OHSS) – can lead to serious complications; discontinue treatment if OHSS is suspected.,Multiple gestations – increased risk of multiple births.,Ovarian torsion – report sudden abdominal pain.,Pulmonary and vascular complications – thromboembolic events; discontinue if suspected.,Ectopic pregnancy and spontaneous abortion – higher rates in ART patients.,Neoplasms – risk of ovarian neoplasms with repeated use.
High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,An organic intracranial lesion (e.g., pituitary tumor),Abnormal uterine bleeding of undetermined origin,Ovarian cyst or enlargement of unknown etiology,Pregnancy,Hypersensitivity to urofollitropin or any component
Hypersensitivity to urofollitropin or any component,High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Known or suspected pregnancy,Ovarian cyst or enlargement of undetermined origin,Abnormal uterine bleeding of undetermined origin,Sex hormone-dependent tumors (e.g., breast, uterus, ovary)
No specific food interactions documented. Maintain adequate hydration to reduce OHSS risk. Avoid excessive alcohol or caffeine as they may affect fertility.
No known food interactions. Maintain normal diet and hydration. Avoid alcohol as it may exacerbate side effects like nausea.
REPRONEX (menotropins) is classified as FDA Pregnancy Category X. Studies have shown that menotropins can cause fetal harm when administered to a pregnant woman. There is no indication for use during pregnancy, as it is used for ovulation induction in infertility. If used inadvertently, there is a risk of multiple gestations and potential for congenital anomalies, but no specific teratogenic pattern has been established. Use is contraindicated in pregnant women.
Pregnancy Category X. Urofollitropin is contraindicated in pregnant women due to risk of fetal harm. First trimester: Ovarian hyperstimulation syndrome (OHSS) and multiple gestations. Second and third trimesters: No direct fetal effects reported, but risks associated with multiple gestation (preterm birth, low birth weight). Maternal OHSS may lead to thromboembolism.
It is unknown whether menotropins are excreted in human milk. Due to the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. No M/P ratio is available.
Urofollitropin is not indicated for use during lactation. No data on excretion in human milk, M/P ratio not established. Use during breastfeeding is contraindicated due to potential for adverse effects on infant hormone levels.
REPRONEX is contraindicated in pregnancy and should not be used. No dosing adjustments are applicable as it is not indicated for use during pregnancy. Pharmacokinetic changes in pregnancy do not apply because the drug is not administered during pregnancy.
No dose adjustment applicable as therapy is discontinued upon confirmed pregnancy. No pharmacokinetic data during pregnancy; drug is not used after conception due to contraindication.
REPRONEX (menotropins) is a gonadotropin preparation containing FSH and LH activity. Monitor estradiol levels and follicular growth via ultrasound to adjust dosing and minimize ovarian hyperstimulation syndrome (OHSS) risk. Avoid use in primary ovarian failure. Administer intramuscularly; rotate injection sites. Concomitant h CG is required for final follicular maturation and ovulation trigger.
BRAVELLE (urofollitropin) is a purified FSH product used for controlled ovarian hyperstimulation. Administer subcutaneously; rotate injection sites. Monitor estradiol levels and follicle growth via ultrasound. Risk of ovarian hyperstimulation syndrome (OHSS); consider using Gn RH antagonist protocols to reduce risk. Do not administer if patient has high baseline FSH levels (>15 IU/L) indicating poor ovarian reserve.
Store REPRONEX in the refrigerator and protect from light.,Administer exactly as prescribed; do not change dose or schedule.,You may experience bloating, pelvic discomfort, or mood swings; report severe abdominal pain, nausea, or rapid weight gain (signs of OHSS) immediately.,Multiple pregnancy is possible; discuss risks with your doctor.,Use barrier contraception until instructed to attempt conception.,Do not drive or operate machinery if dizziness or visual disturbances occur.
Teach proper injection technique and site rotation (abdomen, thigh).,Report immediately if severe pelvic pain, nausea, vomiting, or rapid weight gain occurs (OHSS signs).,Avoid intercourse until instructed to prevent multiple pregnancy.,Inform of multiple pregnancy risk (especially twins).,Store vials in refrigerator (2-8°C) and protect from light.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about REPRONEX vs BRAVELLE, answered by our medical review team.
REPRONEX is a Gonadotropin that works by REPRONEX (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth in women who do not have primary ovarian failure. It acts by binding to FSH receptors on granulosa cells, increasing c AMP and promoting follicular development and estrogen synthesis.. BRAVELLE is a Gonadotropin that works by Bravelle (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth and maturation by binding to FSH receptors on granulosa cells, increasing c AMP production and promoting follicular development.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between REPRONEX and BRAVELLE depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of REPRONEX is: Men: 1000-2500 IU subcutaneously 3 times weekly for 6-12 months. Women: 75-300 IU subcutaneously or intramuscularly daily for 7-12 days.. The standard adult dose of BRAVELLE is: For ovulation induction: 150 IU subcutaneously or intramuscularly once daily for 5 days, starting on day 3 or 5 of menstrual cycle. For controlled ovarian hyperstimulation: 150-225 IU subcutaneously or intramuscularly once daily for 5-7 days, then adjust based on response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between REPRONEX and BRAVELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. REPRONEX is classified as Category C. REPRONEX (menotropins) is classified as FDA Pregnancy Category X. Studies have shown that menotropins can cause fetal harm when administered to a pregnant woman. There is no indica. BRAVELLE is classified as Category C. Pregnancy Category X. Urofollitropin is contraindicated in pregnant women due to risk of fetal harm. First trimester: Ovarian hyperstimulation syndrome (OHSS) and multiple gestatio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.